XML 21 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Sep. 30, 2016
Cash flows from operating activities:          
Net income $ 5,132 $ 2,384 $ 11,960 $ 15,105  
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization 18,365 14,115 36,207 27,897  
Interest expense related to amortization of debt issue costs and debt discount 700 600 1,606 1,184  
Debt pre-payment premiums     0 93  
Stock-based compensation 400 800 901 1,521  
Deferred income taxes     7,099 8,643  
Tax benefit from exercise of stock appreciation rights and vesting of restricted stock     (5,860) (97)  
Net gain on disposition of property, plant and equipment     (216) (46)  
Net loss of unconsolidated joint venture     19 26  
Decrease in trade receivables     19,682 33,538  
Increase in inventories     (14,958) (4,066)  
Decrease in accounts payable and accrued liabilities     (19,413) (36,372)  
Other changes in operating assets and liabilities, net     (2,357) (2,985)  
Net cash provided by (used in) operating activities     34,670 44,441  
Cash flows from investing activities:          
Business acquisitions, net of cash acquired     (10,530) (96,457)  
Purchase of property, plant and equipment (14,193) (13,197) (29,733) (20,882)  
Proceeds from disposition of property, plant and equipment     626 404  
Net decrease (increase) in long-term receivables and deposits     4,890 (1,729)  
Net change in other assets     2,368 (3,817)  
Net cash provided by (used in) investing activities     (32,379) (122,481)  
Cash flows from financing activities:          
Payments on long-term debt     (15,000) (5,874)  
Debt pre-payment premiums     0 (93)  
Dividends paid to non-controlling interest in consolidated subsidiary     (657) (735)  
Employee stock purchases     336 539  
Tax benefit from exercise of stock appreciation rights and vesting of restricted stock     5,860 97  
Net cash provided by (used in) financing activities     (9,461) (6,066)  
Net increase (decrease) in cash and cash equivalents     (7,170) (84,106)  
Cash and cash equivalents, beginning of period     65,298 142,597 $ 142,597
Cash and cash equivalents, end of period $ 58,128 $ 58,491 $ 58,128 $ 58,491 $ 65,298